AGT Antibody - N-terminal region
Catalog Number:
ASB-ARP43614_P050
- Images (5)
| Article Name: | AGT Antibody - N-terminal region |
| Biozol Catalog Number: | ASB-ARP43614_P050 |
| Supplier Catalog Number: | ARP43614_P050 |
| Alternative Catalog Number: | ASB-ARP43614_P050-25UL,ASB-ARP43614_P050-100UL |
| Manufacturer: | Aviva |
| Host: | Rabbit |
| Category: | Proteine/Peptide |
| Application: | WB |
| Species Reactivity: | Canine, Equine, Human, Mouse, Rabbit, Rat, Sheep |
| Immunogen: | The immunogen is a synthetic peptide directed towards the N terminal region of human AGT |
| Alternative Names: | ANHU, hFLT1, SERPINA8 |
| AGT, pre-angiotensinogen or angiotensinogen precursor, is expressed in the liver and is cleaved by the enzyme renin in response to lowered blood pressure. The resulting product, angiotensin I, is then cleaved by angiotensin converting enzyme (ACE) to generate the physiologically active enzyme angiotensin II. The protein is involved in maintaining blood pressure and in the pathogenesis of essential hypertension and preeclampsia. Mutations in this gene are associated with susceptibility to essential hypertension, and can cause renal tubular dysgenesis, a severe disorder of renal tubular development. Defects in this gene have also been associated with non-familial structural atrial fibrillation, and inflammatory bowel disease.The protein encoded by this gene, pre-angiotensinogen or angiotensinogen precursor, is expressed in the liver and is cleaved by the enzyme renin in response to lowered blood pressure. The resulting product, angiotensin I, is then cleaved by angiotensin converting enzyme (ACE) to generate the physiologically active enzyme angiotensin II. The protein is involved in maintaining blood pressure and in the pathogenesis of essential hypertension and preeclampsia. Mutations in this gene are associated with susceptibility to essential hypertension, and can cause renal tubular dysgenesis, a severe disorder of renal tubular development. Defects in this gene have also been associated with non-familial structural atrial fibrillation, and inflammatory bowel disease. Publication Note: This RefSeq record includes a subset of the publications that are available for this gene. Please see the Entrez Gene record to access additional publications. |
|
|
25 ug of the indicated Human whole cell extracts was loaded onto a 10-20% SDS-PAGE gel. 3 ug/mL of the antibody was used in this experiment. |
|
|
WB Suggested Anti-AGT Antibody Titration: 0.2-1 ug/ml ELISA Titer: 1:62500 Positive Control: Human heart |
|
|
Host: Rabbit Target Name: EGFL8 Sample Type: HepG2 Antibody Dilution: 1.0ug/mlAGT is supported by BioGPS gene expression data to be expressed in HepG2 |
|
|
Host: Rabbit Target Name: AGT Sample Tissue: Human Jurkat Whole Cell Antibody Dilution: 1ug/ml |
|
|
AGT antibody - N-terminal region (ARP43614_P050) in Human Heart using Western Blot |
Product Guarantee and Expert Support
